Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ain Holdings Inc. (9627.T)
JPY5,645.00
+53.00 (+0.95%)
JP JPX Healthcare Medical - Pharmaceuticals
Address
5-2-4-30, Higashisapporo 003-0005
Sapporo, JP
Sapporo, JP
CEO
Shoichi Shudo
Website
ainj.co.jp
IPO
2007-12-28
ISIN JP3105250009
Description
Ain Holdings Inc. is a Japanese corporation primarily involved in pharmaceutical dispensing and the management of cosmetic and drug retail outlets. Its dispensing pharmacy division oversees numerous pharmacies, distributes generic medicines, and offers both personnel placement and advisory services. Concurrently, the cosmetic and drug store segment manages stores operating under the AINZ & TULPE brand. The company's other operations include running various retail establishments and engaging in real estate rental. As of April 30, 2021, Ain Holdings operated 1,065 dispensing pharmacies and 69 cosmetic and drug stores. Established in 1969, the company was formerly known as Ain Pharmaciez Inc. before adopting its current name in November 2015, and its headquarters are located in Sapporo, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY5,645.00
+53.00 (+0.95%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
152.7K
Beta
0.26
Float Shares
23.26M
Free Float %
66.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.99% | -2.71% | +3.00% | +3.58% | -13.76% | -14.39% | +7.38% | +9.12% | -18.48% | -22.27% | +598.34% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
5,645.00
DCF (Unlevered)
40,971.80
+625.8%
DCF (Levered)
40,455.34
+616.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
2.13
Grey zone
Piotroski F-Score
3 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+41.8% ★ Q2'26: +44.2% (vs Q2'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+86.0% ★ Q2'26: +269.2% (vs Q2'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+3.5% ★ Q2'26: +0.0% (vs Q2'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.6% Q2'26: +7.5% (vs Q2'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+7.7% ★ Q2'26: +18.6% (vs Q2'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.2% Q2'26: +0.2% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×3.30× Q2'26: 2.23× (vs Q2'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Apr 2015 actual |
Apr 2016 actual |
Apr 2017 actual |
Apr 2018 actual |
Apr 2019 actual |
Apr 2020 actual |
Apr 2021 actual |
Apr 2022 actual |
Apr 2023 actual |
Apr 2024 actual |
Apr 2025 actual |
Apr 2026 5 Rev. Ana. 6 EPS Ana. |
Apr 2027 6 Rev. Ana. 6 EPS Ana. |
Apr 2028 5 Rev. Ana. 5 EPS Ana. |
Apr 2029 2 Rev. Ana. 2 EPS Ana. |
Apr 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
187.90B
est: 189.10B (-0.6%)
|
234.84B
est: 226.76B (+3.6%)
|
248.11B
est: 251.00B (-1.2%)
|
268.39B
est: 270.52B (-0.8%)
|
275.60B
est: 273.91B (+0.6%)
|
292.62B
est: 292.99B (-0.1%)
|
297.31B
est: 299.39B (-0.7%)
|
316.25B
est: 319.65B (-1.1%)
|
358.74B
est: 358.54B (+0.1%)
|
399.82B
est: 408.77B (-2.2%)
|
456.80B
est: 457.70B (-0.2%)
|
648.53B
646.31B – 653.66B
+41.7% YoY
|
732.90B
717.70B – 765.60B
+13.0% YoY
|
788.08B
785.64B – 790.51B
+7.5% YoY
|
888.47B
870.04B – 928.11B
+12.7% YoY
|
955.55B
935.73B – 998.18B
+7.5% YoY
|
| EBITDA |
16.00B
est: 13.25B (+20.8%)
|
20.53B
est: 15.89B (+29.3%)
|
21.91B
est: 17.59B (+24.6%)
|
26.96B
est: 18.95B (+42.2%)
|
24.13B
est: 19.19B (+25.7%)
|
24.51B
est: 20.53B (+19.4%)
|
19.43B
est: 20.98B (-7.4%)
|
22.09B
est: 22.39B (-1.4%)
|
25.77B
est: 25.12B (+2.6%)
|
30.00B
est: 29.38B (+2.1%)
|
31.14B
est: 32.90B (-5.4%)
|
46.61B
46.45B – 46.98B
+41.7% YoY
|
52.68B
51.58B – 55.03B
+13.0% YoY
|
56.64B
56.47B – 56.82B
+7.5% YoY
|
63.86B
62.53B – 66.71B
+12.7% YoY
|
68.68B
67.26B – 71.74B
+7.5% YoY
|
| EBIT |
11.17B
est: 7.84B (+42.5%)
|
14.34B
est: 9.40B (+52.6%)
|
14.56B
est: 10.40B (+40.0%)
|
19.42B
est: 11.21B (+73.2%)
|
16.04B
est: 11.35B (+41.3%)
|
16.07B
est: 12.14B (+32.3%)
|
10.75B
est: 12.41B (-13.4%)
|
13.16B
est: 13.25B (-0.6%)
|
15.93B
est: 14.86B (+7.2%)
|
19.12B
est: 17.68B (+8.1%)
|
16.97B
est: 19.80B (-14.3%)
|
28.05B
27.96B – 28.28B
+41.7% YoY
|
31.70B
31.05B – 33.12B
+13.0% YoY
|
34.09B
33.99B – 34.20B
+7.5% YoY
|
38.43B
37.64B – 40.15B
+12.7% YoY
|
41.34B
40.48B – 43.18B
+7.5% YoY
|
| Net Income |
6.20B
est: 6.53B (-5.1%)
|
7.92B
est: 8.73B (-9.3%)
|
7.95B
est: 9.25B (-14.1%)
|
10.57B
est: 10.72B (-1.4%)
|
9.03B
est: 10.40B (-13.2%)
|
9.18B
est: 9.23B (-0.5%)
|
6.70B
est: 5.92B (+13.0%)
|
7.09B
est: 8.91B (-20.4%)
|
9.24B
est: 9.51B (-2.9%)
|
11.40B
est: 10.90B (+4.6%)
|
9.26B
est: 10.66B (-13.1%)
|
14.07B
12.67B – 17.36B
+32.1% YoY
|
15.70B
15.02B – 16.90B
+11.6% YoY
|
18.24B
16.26B – 19.13B
+16.2% YoY
|
19.67B
17.45B – 21.83B
+7.8% YoY
|
21.63B
21.05B – 22.89B
+10.0% YoY
|
| SGA |
14.70B
est: 13.30B (+10.6%)
|
19.33B
est: 15.95B (+21.2%)
|
21.87B
est: 17.65B (+23.9%)
|
22.43B
est: 19.02B (+17.9%)
|
22.66B
est: 19.26B (+17.7%)
|
23.56B
est: 20.60B (+14.3%)
|
28.03B
est: 21.05B (+33.1%)
|
27.88B
est: 22.48B (+24.0%)
|
29.73B
est: 25.21B (+17.9%)
|
30.47B
est: 36.08B (-15.5%)
|
45.55B
est: 40.39B (+12.8%)
|
57.23B
57.04B – 57.69B
+41.7% YoY
|
64.68B
63.34B – 67.57B
+13.0% YoY
|
69.55B
69.33B – 69.76B
+7.5% YoY
|
78.41B
76.78B – 81.91B
+12.7% YoY
|
84.33B
82.58B – 88.09B
+7.5% YoY
|
| EPS |
195.45
est: 186.36 (+4.9%)
|
249.69
est: 249.08 (+0.2%)
|
250.71
est: 264.11 (-5.1%)
|
310.07
est: 305.85 (+1.4%)
|
254.86
est: 296.89 (-14.2%)
|
259.09
est: 263.40 (-1.6%)
|
189.03
est: 169.09 (+11.8%)
|
201.46
est: 254.16 (-20.7%)
|
262.86
est: 270.48 (-2.8%)
|
324.63
est: 310.73 (+4.5%)
|
264.31
est: 299.48 (-11.7%)
|
403.75
361.48 – 495.35
+34.8% YoY
|
450.72
428.72 – 482.24
+11.6% YoY
|
516.25
463.93 – 545.93
+14.5% YoY
|
560.45
498.00 – 622.90
+8.6% YoY
|
617.40
600.75 – 653.21
+10.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-06-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-06-10 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-06-09 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-06-08 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-06-05 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-06-04 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-06-03 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-06-02 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-06-01 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
7.37B
OE per share TTM
210.35
Owner's Yield
3.70%
Maintenance CapEx ratio
161.49%
Maint CapEx / Avg PPE
10.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 82 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Ageing Population UCITS ETF AGED.L | 0.09% | 783.1K | 0.40% |
| 2 | iShares MSCI Japan Small-Cap ETF SCJ | 0.06% | 166.4K | 0.50% |
| 3 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.06% | 362.4K | 0.58% |
| 4 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.06% | 233.1K | 0.58% |
| 5 | FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD | 0.05% | 334.0K | 0.41% |
| 6 | Schwab Fundamental International Small Company Index ETF FNDC | 0.05% | 1.47M | 0.39% |
| 7 | State Street SPDR S&P International Small Cap ETF GWX | 0.05% | 415.4K | 0.40% |
| 8 | Schwab International Small-Cap Equity ETF SCHC | 0.04% | 2.01M | 0.06% |
| 9 | Avantis International Small Cap Equity ETF AVDS | 0.03% | 90.0K | 0.30% |
| 10 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD dis WSCR.L | 0.03% | 227.3K | 0.23% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
2.60M
Shares Outstanding
35.12M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Azusa Morisawa | Senior Executive Officer & Division Manager of Corporate Audit Officer | — | — |
| Hidehiro Awaji | Senior Executive Officer | — | male |
| Hideki Fujiwara | Senior Executive Officer & Division Manager of Operational Support | — | — |
| Kaori Ishikawa | Senior Executive Officer & Deputy Division Manager of Retail Operations Management | — | female |
| Kiichi Otani | President & Representative Director | — | male |
| Miya Oishi | Representative Senior MD & Director | — | female |
| Nobuyuki Takakura | Division Manager of Sustainability Management & Director | — | male |
| Rieko Kimei | Division Manager of Personnel & Director | — | female |
| Shoichi Shudo | Chairperson of the Board of Directors & Representative Senior MD | — | male |
| Toshihide Mizushima | Representative Senior MD, Division Manager of Retail Operations Management & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9627.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
